From the aTarget RWE, Durham, NC
bDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC
cInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC
dWeill Cornell Medicine Center for Liver Disease, New York, NY
eUniversity of Washington, Seattle, WA
fUniversity of Pennsylvania, Philadelphia, PA
gColumbia University Irving Medical Center Department of Surgery, New York, NY
hDepartment of Population Health Sciences, Duke University, Durham, NC.
Submitted August 29, 2022; accepted January 27, 2023
Due to contractual agreements with the data provider, the data used to produce this manuscript are not available for distribution. The analytic code is available upon request to the corresponding author.
Alexander Breskin and Catherine Wiener contributed equally to this work.
A.B. is an employee of and owns equity in Regeneron Pharmaceuticals. At the time of writing, he was an employee of NoviSci/Target RWE. C.W. is an employee of and owns equity in NoviSci/Target RWE. A.A. has received consulting fees from Merck and Gilead; her institution has received funding from Merck and Gilead for her research. R.S.B. receives research and consulting grants from Gilead, as well as institutional grants from TARGET-HCC, TARGET-NASH, and HCV-TARGET. C.L. receives research funding from Gilead, Pfizer, and Lilly. K.R.R. serves as an advisor to Spark Therapeutics, Mallinckrodt, Novo Nordisk, and Genfit; he receives research support (paid to the University of Pennsylvania) from Gilead, Merck, BMS, Intercept, Exact Sciences, Biovie, Sequana, Grifols, TARGET-HCC, HCV-TARGET, and TARGET-NASH; he serves on a DSMB for Novartis. E.C.V. declares no conflicts of interest. J.M.C. is an employee of and owns equity in Target RWE. A.M. is an employee of and owns equity in Target RWE. M.W.F. is Chief Medical Officer for TARGET RWE and receives personal fees and is a stockholder in the company. M.A.B. serves on scientific advisory committees for AbbVie, Amgen, Astellas/Seagan, Atara Biotherapeutics, Brigham and Women’s Hospital, Kite/Gilead, and Vertex; he receives consulting fees and owns equity in NoviSci/Target RWE.
Supplemental digital content is available through direct URL citations in the HTML and PDF versions of this article (www.epidem.com).
Correspondence: Alexander Breskin, Regeneron Pharmaceuticals, 777 Old Saw Mill River Rd, Tarrytown, NY 10591. E-mail: [email protected].
